Recon: FDA rejects Replimune’s oncolytic virus drug over study issues; Sarepta to halt shipments of Duchenne gene therapy
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States